AbbVie is committed to addressing this public health crisis. We are collaborating with health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of KALETRA®/Aluvia (lopinavir/ritonavir), AbbVie’s antiretroviral therapy for the treatment of HIV, against COVID-19. This includes:

• Supporting clinical studies and basic research with lopinavir/ritonavir, working closely with European health authorities and the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health and U.S. Biomedical Advanced Research and Development Authority (BARDA) to coordinate efforts.
• Partnership with the World Health Organization (WHO) to participate in the World Health Organization’s SOLIDARITY trial testing several potential therapies for COVID-19, including lopinavir/ritonavir in combination with or without interferon.
• Participation in a European multicenter, randomized clinical study (DISCOVERY) on the safety and efficacy of lopinavir/ritonavir in hospitalized COVID-19 patients across multiple countries.
• Partnership with BARDA to support in-vitro testing of lopinavir/ritonavir among other protease and polymerase inhibitors in the U.S.
• Along with industry partners, the company has joined the Innovative Medicines Initiative to support research and discovery of targeted medicines against COVID-19. 
• AbbVie is closely monitoring the data generated through these research collaborations and externally initiated studies to understand if lopinavir/ritonavir is effective in the treatment of COVID-19.

We have also initiated a Phase 2 study of IMBRUVICA in patients with COVID-19 infection. The goal of this study is to determine whether IMBRUVICA is able to improve patient outcomes by diminishing the immune response known as the cytokine storm that contributes to the morbidity and mortality in COVID-19.

We are continuing to closely manage manufacturing and supply chain resources around the world to help ensure our patients continue to receive an uninterrupted supply of their medicines.

We understand your need to know more about the coronavirus. If you are on an AbbVie treatment, please speak with your doctor regarding any questions you may have. Your doctor can provide medical advice to address your individual needs.

Medication assistance

For patients who have lost insurance coverage related to COVID-19, we are here to help.

Through myAbbVie Assist, qualifying patients in the U.S. can receive free AbbVie medicine. If you are unable to pay for your AbbVie medicine due to COVID-19 circumstances, let us help you explore your options. Learn more about myAbbVie Assist.

AbbVie is donating $35 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 global pandemic. AbbVie’s partners are:

• International Medical Corps to help create capacity to treat patients at overburdened hospitals in the U.S. AbbVie’s donation will support the creation and operation of 20 mobile field hospitals to expand available triage at existing facilities, improve patient flow and keep COVID-19 patients separated from other patients. These standalone mobile field hospitals are being built in U.S. hotspots.
• Direct Relief to provide equipment and supplies in the hardest-hit European countries. This support will enable the procurement and delivery of oxygen concentrators, ventilators and personal protective equipment to frontline healthcare workers and patients.
• Feeding America to protect the most vulnerable, including the elderly, by enabling access to food and essential household supplies with minimal contact. Feeding America has created a new model of home delivery and drive-through service.

Read the full announcement and access the press kit

Included in the $35 million is a reserve of $5 million for a new AbbVie COVID-19 Community Resilience Fund. On May 21, AbbVie announced the 26 nonprofit recipients that will help front-line healthcare workers and vulnerable populations in hard-hit communities. Learn more.

AbbVie is also doubling the AbbVie Foundation match for COVID-19-related contributions by employees. Instead of the typical 1:1 match, the AbbVie Foundation will match $2 to every $1 employees donate to a qualified nonprofit.

If you are a registered healthcare provider with questions about COVID-19 and AbbVie medications or adverse event reporting, please visit AbbVie’s medical information website, www.abbviemedinfo.com.

If you are an employee that is being impacted by the COVID-19 pandemic and need assistance, the AbbVie Employee Assistance Fund (AEAF) may be able to help. 
Click here to apply and for more information.

AbbVie is focused on ensuring the safety of our employees while we continue to make the vital medicines our patients depend on.

AbbVie has taken the following steps to protect the health of our employees:

• A significant number of our employees who have jobs that can be done remotely are now working from home.
  
• For those people who need to be at an AbbVie facility to do their job, we’ve taken aggressive steps to limit exposure risk and keep our worksites as safe as possible.
  
• We support social distancing at all facilities where possible and encourage all employees to practice recommended safety measures.
  
• Enacted strict travel restrictions in accordance with government guidance.
  

We will continue to closely monitor this evolving situation during this unprecedented global health crisis. 

We are providing special bonus payments to eligible essential employees during this crisis who are working onsite, in recognition of their contributions toward the company and our patients.
 

AbbVie is committed to supporting the relief efforts of the COVID-19 pandemic crisis. As a global healthcare company, some of our employees may have the experience needed to support government and community organizations during this crisis. The company provides a professional service policy for AbbVie employees with relevant medical, pharmaceutical, research and development, science, public health and public safety skills, knowledge, training and experience who desire, are requested, or mandated to serve as volunteers during times of pandemic crisis. AbbVie colleagues will continue to receive their full pay, benefits, and be able to return to their position after completing their service.

KALETRA (lopinavir/ritonavir) is approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (14 days and older). Although research for its use as a potential treatment for COVID-19 remains ongoing, it is not approved to treat COVID-19 and should only be used in the clinical trial setting as the safety and effectiveness has not been established for this use. If you are a patient, please contact your healthcare provider for more information.

AbbVie is constantly monitoring and taking precautions to protect the safety of our study participants, clinical trial site staff and our employees. We will continue to evaluate any local support our study participants may require to maintain their safe involvement in our clinical trials.

AbbVie Medical Information for healthcare providers
www.abbviemedinfo.com

Centers for Disease Control Coronavirus disease 2019 (COVID-19)
CDC website

World Health Organization Coronavirus disease (COVID-19) webpage
WHO website

AbbVie Media Relations
Contact us